Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
31 mars 2022 07h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
22 mars 2022 07h30 HE
|
Windtree Therapeutics
WARRINGTON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
15 mars 2022 07h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Present at Oppenheimer’s 32nd Annual Healthcare Conference
10 mars 2022 08h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions...
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome
01 févr. 2022 07h30 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
15 déc. 2021 08h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation
22 nov. 2021 08h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
10 nov. 2021 16h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
25 oct. 2021 07h30 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for...
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock
14 oct. 2021 07h30 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for...